| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | CT3.5 |
| WB Predicted band size | 39 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human MAGEB3 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇与MAGEB3抗体相关的文献摘要(文献名称与作者为虚构示例，供参考)：
---
1. **文献名称**: *MAGEB3 as a novel cancer-testis antigen in melanoma: antibody validation and clinical significance*
**作者**: Smith A, et al.
**摘要**: 研究验证了高特异性MAGEB3单克隆抗体在黑色素瘤组织中的检测能力，发现MAGEB3在转移性黑色素瘤中高表达，提示其可作为免疫治疗靶点或预后标志物。
---
2. **文献名称**: *Development of a polyclonal antibody against MAGEB3 for functional studies in germ cell tumors*
**作者**: Chen L, et al.
**摘要**: 报道了一种新型多克隆抗体的开发，通过免疫印迹和免疫荧光验证其特异性，并发现MAGEB3在睾丸生殖细胞肿瘤中异常表达，可能与肿瘤增殖通路相关。
---
3. **文献名称**: *Targeting MAGEB3 with therapeutic antibodies enhances anti-tumor immunity in vivo*
**作者**: Rodriguez J, et al.
**摘要**: 研究利用人源化MAGEB3抗体在小鼠模型中证明其可通过抗体依赖性细胞毒性(ADCC)抑制肿瘤生长，为MAGEB3靶向免疫治疗提供临床前依据。
---
注：以上文献信息为模拟生成，实际研究中建议通过PubMed或Web of Science以“MAGEB3 antibody”为关键词检索真实文献。
The MAGEB3 antibody targets the MAGEB3 protein, a member of the melanoma-associated antigen (MAGE) family. MAGE genes are typically silent in normal adult tissues but reactivated in various cancers, making them potential targets for cancer immunotherapy. MAGEB3. located on the X chromosome, encodes a cancer-testis antigen (CTA) expressed in malignancies like melanoma, lung cancer, and head/neck squamous cell carcinoma. Its restricted expression in healthy tissues (primarily testes) and immunogenic properties have driven interest in MAGEB3 as a biomarker and therapeutic target.
MAGEB3 antibodies are critical tools for studying its biological roles, including cell proliferation, apoptosis resistance, and immune evasion mechanisms. They enable detection of MAGEB3 protein expression in tumor samples, aiding in cancer diagnosis and prognosis. Additionally, these antibodies support research into MAGEB3's interaction with cellular pathways, such as E3 ubiquitin ligase complexes, and its potential role in promoting tumorigenesis.
Clinically, MAGEB3 antibodies are explored for immunotherapeutic strategies, including antibody-drug conjugates, CAR-T cells, or vaccines. However, challenges like tumor heterogeneity and variable MAGEB3 expression levels across patients necessitate further validation. Despite this, MAGEB3 remains a promising candidate for targeted cancer therapies, with ongoing studies aiming to optimize antibody specificity and therapeutic efficacy.
×
